Chapter 7 134 94. Klammt C, Maslennikov I, Bayrhuber M, Eichmann C, Vajpai N, Chiu EJ, et al. Facile backbone structure determination of human membrane proteins by NMR spectroscopy. Nature methods. 2012;9(8):834-9. 95. Woo IS, Jin H, Kang ES, Kim HJ, Lee JH, Chang KC, et al. TMEM14A inhibits N-(4hydroxyphenyl)retinamide-induced apoptosis through the stabilization of mitochondrial membrane potential. Cancer Lett. 2011;309(2):190-8. 96. Lee SH, Yoo TH, Nam BY, Kim DK, Li JJ, Jung DS, et al. Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. American journal of physiology Renal physiology. 2009;297(5):F1381-90. 97. Zhou LL, Cao W, Xie C, Tian J, Zhou Z, Zhou Q, et al. The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis. Kidney Int. 2012;82(7):759-70. 98. Zhou LL, Hou FF, Wang GB, Yang F, Xie D, Wang YP, et al. Accumulation of advanced oxidation protein products induces podocyte apoptosis and deletion through NADPHdependent mechanisms. Kidney Int. 2009;76(11):1148-60. 99. Cardoso VG, Goncalves GL, Costa-Pessoa JM, Thieme K, Lins BB, Casare FAM, et al. Angiotensin II-induced podocyte apoptosis is mediated by endoplasmic reticulum stress/ PKC-delta/p38 MAPK pathway activation and trough increased Na(+)/H(+) exchanger isoform 1 activity. BMC Nephrol. 2018;19(1):179. 100. Tao Y, Yazdizadeh Shotorbani P, Inman D, Das-Earl P, Ma R. Store-operated Ca(2+) entry inhibition ameliorates high glucose and AngⅡ induced podocyte apoptosis and mitochondria damage. American journal of physiology Renal physiology. 2023. 101. Yamamoto K, Okabe M, Tanaka K, Yokoo T, Pastan I, Araoka T, et al. Podocytes are lost from glomeruli before completing apoptosis. American journal of physiology Renal physiology. 2022;323(5):F515-F26. 102. Elmonem MA, Khalil R, Khodaparast L, Khodaparast L, Arcolino FO, Morgan J, et al. Cystinosis (ctns) zebrafish mutant shows pronephric glomerular and tubular dysfunction. Sci Rep. 2017;7:42583. 103. Nagata M. Podocyte injury and its consequences. Kidney Int. 2016;89(6):1221-30. 104. Kok FO, Shin M, Ni CW, Gupta A, Grosse AS, van Impel A, et al. Reverse genetic screening reveals poor correlation between morpholino-induced and mutant phenotypes in zebrafish. Dev Cell. 2015;32(1):97-108. 105. Drummond IA. Kidney development and disease in the zebrafish. Journal of the American Society of Nephrology : JASN. 2005;16(2):299-304. 106. Gahl WA, Thoene JG, Schneider JA. Cystinosis. The New England journal of medicine. 2002;347(2):111-21. 107. Town M, Jean G, Cherqui S, Attard M, Forestier L, Whitmore SA, et al. A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nat Genet. 1998;18(4):319-24. 108. Dohil R, Fidler M, Barshop BA, Gangoiti J, Deutsch R, Martin M, et al. Understanding intestinal cysteamine bitartrate absorption. J Pediatr. 2006;148(6):764-9. 109. Besouw M, Blom H, Tangerman A, de Graaf-Hess A, Levtchenko E. The origin of halitosis in cystinotic patients due to cysteamine treatment. Molecular genetics and metabolism. 2007;91(3):228-33. 110. Ariceta G, Lara E, Camacho JA, Oppenheimer F, Vara J, Santos F, et al. Cysteamine (Cystagon(R)) adherence in patients with cystinosis in Spain: successful in children and a challenge in adolescents and adults. Nephrol Dial Transplant. 2015;30(3):475-80. 111. Cherqui S, Sevin C, Hamard G, Kalatzis V, Sich M, Pequignot MO, et al. Intralysosomal Cystine Accumulation in Mice Lacking Cystinosin, the Protein Defective in Cystinosis. Molecular and Cellular Biology. 2002;22(21):7622-32.
RkJQdWJsaXNoZXIy MTk4NDMw